FOLH1 and prostate cancer: Especially the introduction of Glu-NH-CO-NH-Lys-[68Gallium-(HBED-CC)] (68Ga-PSMA-11) [4,5] is considered to have substantially improved detectability and staging of prostate cancer in both PET/CT [5–10] and, more recently, PET/MRI [11–14].